(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
03 June 2021 (03.06.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/104487 A1

(51) International Patent Classification:
A61K 31/505 (2006.01) *A61P 35/00* (2006.01)
A61K 31/704 (2006.01)

(21) International Application Number:
PCT/CN2020/132422

(22) International Filing Date:
27 November 2020 (27.11.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/941,891 29 November 2019 (29.11.2019) US
63/072,281 31 August 2020 (31.08.2020) US

(71) Applicant: **APTORUM THERAPEUTICS LIMITED** [CN/CN]; Unit 232, Building 12W, Hong Kong Science Park, N.T., Hong Kong, Hong Kong (CN).

(72) Inventors: **LEE, Wai Yip Thomas**; Unit 232, Building 12W, Hong Kong Science Park, N.T., Hong Kong, Hong Kong (CN). **POON, Chung Sing Daniel**; Unit 232, Building 12W, Hong Kong Science Park, N.T., Hong Kong, Hong Kong (CN). **LAI, Ka Lun**; Unit 232, Building 12W, Hong Kong Science Park, N.T., Hong Kong, Hong Kong (CN). **HUANG, Junzhe**; Unit 232, Building 12W, Hong Kong Science Park, N.T., Hong Kong, Hong Kong (CN). **LI, Ho Yin**; Unit 232, Building 12W, Hong Kong Science Park, N.T., Hong Kong, Hong Kong (CN).

(74) Agent: **IDEA INTELLECTUAL (SHENZHEN) IP AGENCY**; Room 801A, City University of Hong Kong Shenzhen Research Institute Building, 8 Yuexing 1st Road Hi-Tech District Community, Yue Hai Street, Nanshan District, Shenzhen, Guangdong 518057 (CN).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:
— *with international search report (Art. 21(3))*

WO 2021/104487 A1

(54) Title: COMPOSITION INCLUDING RILPIVIRINE AND USE THEREOF FOR TREATING TUMORS OR CANCER



(I)



(II)

(57) Abstract: A composition and use thereof for preventing the growth of and/or treating cancero-us tumors and/or delaying onset of cancer from tumor-initiating cells. The composit-ion includes an effective amount of a compound of Formula (I) or Formula (II) or any pharmaceutically acceptable salt thereof. The composition is administered alone or in combination with one or more chemotherapeutic agents and/or biological agents. The use may include administering the composition of the present invention with or without the chemotherapeutic, biological, or other cancer treatment agent to a subject in need thereof intravenously, parenterally, nasally, topically or locally, orally, or by liposome, implant or via vessel-targeted nanosuspension delive-ry.